Amgen: Melanoma trials

The registry lists 18 Melanoma studies with Amgen as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 4Phase 2 7Phase 3 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedNCT04068181Phase 2Results posted
• Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaCompletedNCT03064763Phase 1Results posted
• An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)CompletedNCT02574260Phase 2Results posted
• Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected MelanomaCompletedNCT02366195Phase 2Results posted
• Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaTerminatedNCT02263508Phase 3Results posted
• Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for MelanomaCompletedNCT02211131Phase 2Results posted
• Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecCompletedNCT02014441Phase 2Results posted
• Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedNCT01740297Phase 1/2Results posted
• An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3Results posted
• Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedNCT00769704Phase 3Results posted
• A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant MelanomaCompletedNCT00289016Phase 2Results posted
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3
• A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3
• Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionCompletedNCT02910557
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c MelanomaNo longer availableNCT02297529
• Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c MelanomaNo longer availableNCT02147951